Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2016

Pirazzoli Valentina, Ayeni Deborah, Meador Catherine B, Sanganahalli Basavaraju G, Hyder Fahmeed, de Stanchina Elisa, Goldberg Sarah B, Pao William, Politi Katerina

Abstract excerpt

PURPOSE: The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and afatinib, have transformed the treatment of advanced EGFR-mutant lung adenocarcinoma. However, almost all patients who respond develop acquired resistance on average approximately 1 year after starting therapy. Resistance is commonly due to a secondary mutation in EGFR (EGFR(T790M)). We previously found that the combination of the EGFR TKI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Drug Evaluation, Preclinical

Share to Erlotinib Hydrochloride

Share to Mice, Nude

Share to Neoplasm Recurrence, Local

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 26341921
DOI: 10.1158/1078-0432.CCR-15-0620
PMCID: PMC4715986

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.PMID 26341921Read ↗

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.Semantic proximity Read ↗

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.Semantic proximity Read ↗

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Semantic proximity Read ↗

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.Semantic proximity Read ↗

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.Semantic proximity Read ↗

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.Semantic proximity Read ↗

First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.Semantic proximity Read ↗

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.Semantic proximity Read ↗

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.Semantic proximity Read ↗

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.Semantic proximity Read ↗

Afatinib restrains K-RAS-driven lung tumorigenesis.Semantic proximity Read ↗

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.